Durability of first line antiretroviral therapy : reasons and predictive factors for modifications in a Swaziland cohort

Show simple item record

dc.contributor.author Takuva, Simbarashe G.
dc.contributor.author Louwagie, Goedele M.C.
dc.contributor.author Zuma, Khangelani
dc.contributor.author Okello, Velephi
dc.date.accessioned 2012-04-13T11:29:01Z
dc.date.available 2012-04-13T11:29:01Z
dc.date.issued 2012-01-26
dc.description.abstract BACKGROUND: Optimizing initial antiretroviral therapy (ART) regimens is critical in improving the durability of treatment efficacy and patient prognosis. Reasons for and risk factors relating to the need for ART modifications were evaluated in an outpatient cohort in Mbabane, Swaziland. METHODS: We examined routine clinical data for 782 patients initiating first-line ART between 1 March 2006 and 31 March 2008. Treatment modification was defined as either a first time single drug substitution or first time regimen switch. Multivariate piecewise Cox regression models were used to identify risk factors for ART modification. RESULTS: Over a median follow-up period of 21 months, 17.5% of patients modified their regimen. Drug toxicity (incidence rate of 6.3 per 100 person years (95% CI 5.2-7.7)) accounted for 76.6% of the reasons for modification. Drug contra-indications (incidence rate 9.5 per 100 person years (95% CI 6.5-13.9)), namely tuberculosis (13.1%) and pregnancy (6.6%), accounted for 19.7% of modifications. In the adjusted multivariate Cox piecewise regression model, beyond 11 months on ART, a baseline CD4 cell count <200 cells/mm3 (HR 4.42; 95% CI: 1.62 – 12.1), having stavudine (d4T) in the initial regimen (HR 2.64; 95% CI: 1.56 – 4.46), baseline weight > 60kg (HR 2.40; 95% CI: 1.43 – 4.04) and increase in age (HR 1.03; 95% CI: 1.00 – 1.05) increased the risk of modification. CONCLUSIONS: Initiating ART earlier, at higher CD4 counts, avoiding drugs with poor safety profiles, such as d4T, and identifying individuals who may require tuberculosis treatment or may become pregnant could reduce modification rates. This would improve regimen tolerability, while preserving future treatment options. en_US
dc.description.sponsorship The Swaziland government and the Global Fund to Fight Tuberculosis, HIV and Malaria. en_US
dc.description.uri http://omicsonline.org/jaahome.php en_US
dc.identifier.citation Takuva S, Louwagie G, Zuma K, Okello V (2012) Durability of First Line Antiretroviral Therapy: Reasons and Predictive Factors for Modifications in a Swaziland Cohort. J Antivir Antiretrovir 4: 014-020. DOI : 10.4172/jaa.1000040 en_US
dc.identifier.issn 1948-5964
dc.identifier.other 10.4172/jaa.1000040
dc.identifier.uri http://hdl.handle.net/2263/18569
dc.language.iso en en_US
dc.publisher OMICS Publishing en_US
dc.rights © 2012 Takuva S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. en_US
dc.subject First line ART en_US
dc.subject Regimen durability en_US
dc.subject Antiretroviral drug modifications en_US
dc.subject Swaziland en_US
dc.subject.lcsh Tuberculosis -- Treatment en
dc.subject.lcsh AIDS (Disease) -- Treatment en
dc.title Durability of first line antiretroviral therapy : reasons and predictive factors for modifications in a Swaziland cohort en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record